RARE Earnings Ultragenyx Pharmaceutical Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–32 of 32
| Q2 2026 | 2026-06-30 | -2.73 | 2026-08-05 | 10-Q |
| Q1 2026 | 2026-03-31 | -1.84 | 2026-05-06 | 10-Q |
| FY 2025 | 2025-12-31 | -5.83 | 2026-02-18 | 10-K |
| Q3 2025 | 2025-09-30 | -4.55 | 2025-11-05 | 10-Q |
| Q2 2026 | 2025-06-30 | -2.73 | 2026-08-05 | 10-Q |
| Q1 2026 | 2025-03-31 | -1.57 | 2026-05-06 | 10-Q |
| FY 2025 | 2024-12-31 | -6.29 | 2026-02-18 | 10-K |
| Q3 2025 | 2024-09-30 | -4.91 | 2025-11-05 | 10-Q |
| Q2 2025 | 2024-06-30 | -3.54 | 2025-08-06 | 10-Q |
| Q1 2025 | 2024-03-31 | -2.03 | 2025-05-07 | 10-Q |
| FY 2025 | 2023-12-31 | -8.25 | 2026-02-18 | 10-K |
| Q3 2024 | 2023-09-30 | -6.81 | 2024-11-06 | 10-Q |
| Q2 2024 | 2023-06-30 | -4.58 | 2024-08-02 | 10-Q |
| Q1 2024 | 2023-03-31 | -2.33 | 2024-05-03 | 10-Q |
| FY 2024 | 2022-12-31 | -10.12 | 2025-02-19 | 10-K |
| Q3 2023 | 2022-09-30 | -7.96 | 2023-11-03 | 10-Q |
| Q2 2023 | 2022-06-30 | -4.45 | 2023-08-04 | 10-Q |
| Q1 2023 | 2022-03-31 | -2.19 | 2023-05-05 | 10-Q |
| FY 2023 | 2021-12-31 | -6.70 | 2024-02-21 | 10-K |
| Q3 2022 | 2021-09-30 | -4.91 | 2022-11-03 | 10-Q |
| Q2 2021 | 2021-06-30 | -3.84 | 2021-08-03 | 10-Q |
| FY 2022 | 2020-12-31 | -3.07 | 2023-02-17 | 10-K |
| FY 2020 | 2020-09-30 | -1.13 | 2021-02-12 | 10-K |
| Q2 2021 | 2020-06-30 | -1.59 | 2021-08-03 | 10-Q |
| FY 2020 | 2020-03-31 | -2.05 | 2021-02-12 | 10-K |
| Q2 2020 | 2019-06-30 | -3.54 | 2020-07-30 | 10-Q |
| Q1 2019 | 2019-03-31 | -1.82 | 2019-05-07 | 10-Q |
| FY 2019 | 2018-12-31 | -1.73 | 2020-02-14 | 10-K |
| FY 2019 | 2018-09-30 | -1.74 | 2020-02-14 | 10-K |
| FY 2019 | 2018-06-30 | -1.06 | 2020-02-14 | 10-K |
| FY 2019 | 2018-03-31 | 0.62 | 2020-02-14 | 10-K |
| Q1 2018 | 2017-03-31 | -1.63 | 2018-05-08 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.